These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 7524542)

  • 1. Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1.
    Kuritzkes DR; Bell S; Bakhtiari M
    AIDS; 1994 Jul; 8(7):1017-9. PubMed ID: 7524542
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts.
    Angarano G; Monno L; Appice A; Giannelli A; Romanelli C; Fico C; Pastore G
    AIDS; 1994 Jul; 8(7):1013-4. PubMed ID: 7524541
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Dis Markers; 1990; 8(3):163-4. PubMed ID: 1703061
    [No Abstract]   [Full Text] [Related]  

  • 6. [Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].
    Salomon HE; Pampuro SE; Gu Z; Montaner JS; Libonatti O; Wainberg MA
    Rev Argent Microbiol; 1995; 27(4):214-29. PubMed ID: 8850135
    [No Abstract]   [Full Text] [Related]  

  • 7. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
    Rusconi S; De Pasquale MP; Milazzo L; Kurtagic S; Bulgheroni E; Citterio P; Galazzi M; La Seta Catamancio S; Galli M
    Antivir Ther; 1998; 3(4):203-7. PubMed ID: 10682139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
    Eastman PS; Urdea M; Besemer D; Stempien M; Kolberg J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):264-73. PubMed ID: 7540490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
    Delaugerre C; Marcelin AG; Soulié C; Chaix ML; Katlama C; Girard PM; Calvez V; Morand-Joubert L
    AIDS; 2007 Jun; 21(10):1365-7. PubMed ID: 17545716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary infection with zidovudine-resistant HIV.
    Masquelier B; Lemoigne E; Pellegrin I; Douard D; Sandler B; Fleury HJ
    N Engl J Med; 1993 Oct; 329(15):1123-4. PubMed ID: 8371739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.